Initial interest in UK early access to medicines scheme, but cost considerations still a concern
This article was originally published in SRA
Executive Summary
More details of how the UK's newly launched early access to medicines scheme (EAMS) will work, including the point at which a drug might be made available pre-licensing, have emerged after the pharmaceutical and biotech industry associations, the ABPI and the BIA, held a meeting to discuss the ins and outs of the scheme with industry stakeholders.